Divi's Laboratories Limited

NSE DIVISLAB.NS

Divi's Laboratories Limited Total Non-Current Liabilities for the year ending March 31, 2024: USD 74.45 M

Divi's Laboratories Limited Total Non-Current Liabilities is USD 74.45 M for the year ending March 31, 2024, a 7.24% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Divi's Laboratories Limited Total Non-Current Liabilities for the year ending March 31, 2023 was USD 69.42 M, a 16.89% change year over year.
Divi's Laboratories Limited Total Non-Current Liabilities for the year ending March 31, 2022 was USD 59.39 M, a 18.50% change year over year.
Divi's Laboratories Limited Total Non-Current Liabilities for the year ending March 31, 2021 was USD 50.12 M, a 26.34% change year over year.
Divi's Laboratories Limited Total Non-Current Liabilities for the year ending March 31, 2020 was USD 39.67 M, a 17.64% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NSE: DIVISLAB.NS

Divi's Laboratories Limited

CEO	Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
IPO Date	March 12, 2003
Location	India
Headquarters	Divi Towers
Employees	9,741
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

Key trends

Past 5 years